Lipid Signaling Pathways in Cancer


+ show speakers and program
Sunday, July 22, 2012
4:00p.m. – 9:00p.m. FASEB Conference Office Opens for Registration
6:00p.m. – 7:00 p.m. FASEB Opening Reception
7:00p.m. – 8:30 p.m. Buffet Dinner
8:45p.m. – 9:45p.m. Philip N. Tsichlis*, Tufts University
“Akt in animal models of cancer”
Monday, July 23, 2012
7:30a.m. – 9:00a.m. Breakfast
Session 1: 9:00 AM -12:30 PM PI3 Kinase / AKT signaling in cancer
Chair: Alex Toker*, Harvard University
This activity is not being planned in accordance with the ACCME Standards for Commercial Support. AMA PRA Category
1 Credit(s)™ will not be offered.
9:00 AM - 9:40 AM Lew Cantley, Harvard University
“Role of inositol polyphosphate 4-phosphatase in tumor
suppression”
9:40 AM -10:20 AM Philip A. Dennis*, National Cancer Institute
“Akt / mTOR signaling in tobacco-induced lung cancer”
10:20 AM -10:35 AM Group photo & Coffee Break
10:35 AM - 11:15 AM Mahesh P. Gupta, University of Chicago
“Acetylation of Akt and PDK1: Role of tumorigenesis”
11:15 AM - 11:55 AM Alex Toker*, Harvard University
“P13K / Akt signaling in breast cancer cell invasion”
12:00 PM -1:00 PM Lunch
1:00 PM – 4:00 PM Free Afternoon
4:00 PM –6:00 PM Poster Session
6:00 PM – 7:00 PM Dinner
Session 2: 7:00p.m. – 10:00p.m Protein Kinase C Signaling and Cancer
Chair: Mary Reyland*, University of Colorado
7:00 PM - 7:40 PM Jennifer D. Black*, Roswell Park Cancer Institute
“PKCalpha in cell cycle control and cancer cell proliferation”
7:40 PM - 8:20 PM Nicole R. Murray*, Mayo Clinic
“PKC isozymes in pancreatic cancer”
8:20 PM – 8:35 PM Coffee Break
8:35 PM – 9:15 PM Michael Leitges*, University of Oslo
“Animals Models in the study of PKC functions in cancer”
9:15 PM – 9:55 PM Mary Reyland*, University of Colorado
“PKCdelta in cancer cell proliferation and survival”
10:00 PM – Midnight Bar Open (Full Cash Bar)
Tuesday, July 24, 2012
7:30a.m. – 9:00a.m. Breakfast
Session 3: 9:00 AM -12:30 PM Atypical PKCs in Cancer
Chair: Alan P. Fields*, Mayo Clinic
This activity is not being planned in accordance with the ACCME Standards for Commercial Support. AMA PRA Category
1 Credit(s)™ will not be offered.
9:00 AM - 9:40 AM Neil MacDonald*, Cancer UK LRI
“Regulation of aPKC activity”
9:40 AM -10:20 AM Finian Martin*, University College Dublin
“PKCzeta in mammary acinus formation and cancer”
10:20 AM -10:35 AM Coffee Break
10:35 AM - 11:15 AM Alan P. Fields*, Mayo Clinic
PKCiota in human tumor initiation, progression and
metastasis”
11:15 AM - 11:55 AM Emerging Themes / Junior Speakers
12:00 PM -1:00 PM Lunch
1:00 PM – 6:00 PM Free Afternoon
6:00 PM – 7:00 PM Dinner
Session 4: 7:00p.m. – 10:00p.m Phospholipases in Cancer
Chair: John Sondek*, University of North Carolina
7:00 PM - 7:40 PM Matilda Katan*, Cancer Research UK
“Phospholipase C enzymes and cancer”
7:40 PM - 8:20 PM Raphael Nemenoff*, University of Colorado
“Phospholipase A2 in lung cancer”
8:20 PM – 8:35 PM Coffee Break
8:35 PM – 9:15 PM Michael A. Frohman*, Stony Brook University
Phospholipase D signaling in cancer”
9:15 PM – 9:55 PM John Sondek*, University of North Carolina
“Structural analysis of phospholipase C isozyme function”
10:00 PM – Midnight Bar Open (Full Cash Bar)
Wednesday, July 25, 2012
7:30a.m. – 9:00a.m. Breakfast
Session 5: 9:00 AM -12:30 PM Novel diacylglycerol targets in cancer
Chair: Marcelo G. Kazanietz*, University of Pennsylvania
This activity is not being planned in accordance with the ACCME Standards for Commercial Support. AMA PRA Category
1 Credit(s)™ will not be offered.
9:00 AM - 9:40 AM TBN
9:40 AM -10:20 AM Matthew K. Topham*, University of Utah
“Diacylglycerol kinase family members in cancer”
10:20 AM -10:35 AM Coffee Break
10:35 AM - 11:15 AM Marcelo Kazanietz*, University of Pennsylvania
“Chimaerins: linking DAG and Rho GTPase singaling in
cancer”
11:15 AM - 11:55 AM Emerging Themes / Junior Speakers
12:00 PM -1:00 PM Lunch
1:00 PM – 2:30 PM “Meet the Expert” Session
2:30 PM –6:00 PM Free Afternoon
6:00 PM – 7:00 PM Dinner
Session 6: 7:00p.m. – 10:00p.m Lipid modifications of cancer signaling molecules
Chair: Anne J. Ridley*, King’s College London
7:00 PM - 7:40 PM Carol Williams*, Medical College of Wisconsin
“Role of SMG-GDS in GTPase processing and cancer”
7:40 PM - 8:20 PM TBN
8:20 PM – 8:35 PM Coffee Break
8:35 PM – 9:15 PM Anne J. Ridley*, King’s College London
“Rho GTPases in cancer cell migration and invasion”
9:15 PM – 9:55 PM Emerging Themes / Junior Speakers
10:00 PM – Midnight Bar Open (Full Cash Bar)
Thursday, July 26, 2012
7:30a.m. – 9:00a.m. Breakfast
Session 7: 9:00 AM -12:30 PM Integration of lipid signaling pathways
Chair: Peter Parker*, Cancer UK
9:00 AM - 9:40 AM Roger L. Williams*, Cambridge University
This activity is not being planned in accordance with the ACCME Standards for Commercial Support. AMA PRA Category
1 Credit(s)™ will not be offered.
“Multi-vesicular bodies and aberrant cancer signaling”
9:40 AM -10:20 AM Alexandra Newton*, University of California, San Diego
“Role of lipid phosphatases in signal termination”
10:20 AM -10:35 AM Coffee Break
10:35 AM - 11:15 AM Peter Parker*, Cancer UK
“Spatial regulation of lipid signaling”
11:15 AM - 11:55 AM Emerging Themes / Junior Speakers
12:00 PM -1:00 PM Lunch
1:00 pm – 6:00 PM Free Afternoon
6:00 PM – 7:00 PM Dinner
Session 8: 7:00p.m. – 10:00p.m Novel lipids and lipid receptors in cancer
Chair: David N. Brindley*, University of Alberta
7:00 PM - 7:40 PM TBN
7:40 PM - 8:20 PM David Moore*, Baylor College of Medicine
“Bile acids, FXR and cancer”
8:20 PM – 8:35 PM Coffee Break
8:35 PM – 9:15 PM David N. Brindley*, University of Alberta
“Lipid phosphate phosphatases in cancer”
9:15 PM – 9:55 PM Emerging Themes / Junior Speakers
10:00 PM – Midnight Bar Open (Full Cash Bar)
Friday, July 27, 2012
7:30 AM – 8:30 AM Breakfast
8:30 AM – 10:30 AM Lipid signaling pathways in cancer treatment
Chair: Paul Workman*, Cancer UK
8:30 AM – 9:10 AM Channing Der*, University of North Carolina
“Targeting Ras and Ras-related proteins for cancer therapy”
9:10 AM – 9:50 AM Jane Wang*, University of Pittsburgh
“PKD inhibitors as therapeutics”
This activity is not being planned in accordance with the ACCME Standards for Commercial Support. AMA PRA Category
1 Credit(s)™ will not be offered.
9:50 AM – 10:30 AM Paul Workman*, Cancer UK
“Structure-based design of P13 kinase inhibitors”

22 Jul - 27 Jul 2012

Steamboat
United States of America
meeting website